Newsroom

September 2017

• 
  Story Sep 28, 2017 Discovery

  Novartis and UC Berkeley take on “undruggable” proteins in new collaboration

  Researchers from industry and academia will leverage new chemistry to hit difficult drug targets.

• In The News Sep 28, 2017

  Novartis Access and government of Cameroon sign agreement to fight chronic diseases

  Cameroon faces a serious increase in chronic diseases like heart disease, asthma, cancer and diabetes. This agreement complements the government’s ongoing efforts by improving access to affordable…
• Press release Sep 28, 2017

  Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets

  Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer  New Novartis-Berkeley Center for Proteomics and…
• Press release Sep 22, 2017

  Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries

  CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has…
• Press release Sep 20, 2017

  Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

  Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1]   As the first and only therapy for advanced SM…
• 
  Story Sep 18, 2017 Patient Perspectives

  Led by Steven Taylor, the Sjögren’s Syndrome Foundation is raising awareness of a little-known autoimmune disease

• Press release Sep 16, 2017

  Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption

  OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1]  Should a treatment pause be necessary, data showed almost…
• Press release Sep 14, 2017

  Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study

  51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently under…
• Press release Sep 13, 2017

  Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data

  Cosentyx® (secukinumab) is the first and only fully human IL-17A  inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1]  Landmark data show that PASI…
• Press release Sep 12, 2017

  Sandoz proposed biosimilar rituximab accepted for review by the FDA

  Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis[1] Sandoz believes the comprehensive data package submitted to the FDA for review confirms…
• Press release Sep 11, 2017

  Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

  The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified…
• Press release Sep 07, 2017

  Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies

  AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need Dedicated…